Zymeworks Inc
NASDAQ:ZYME

Watchlist Manager
Zymeworks Inc Logo
Zymeworks Inc
NASDAQ:ZYME
Watchlist
Price: 14.3 USD 0.7% Market Closed
Market Cap: 989m USD
Have any thoughts about
Zymeworks Inc?
Write Note

Zymeworks Inc
Deferred Income Tax

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zymeworks Inc
Deferred Income Tax Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Deferred Income Tax CAGR 3Y CAGR 5Y CAGR 10Y
Zymeworks Inc
NASDAQ:ZYME
Deferred Income Tax
$3.5m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Deferred Income Tax
$2.7B
CAGR 3-Years
-9%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Deferred Income Tax
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Deferred Income Tax
$1.7B
CAGR 3-Years
N/A
CAGR 5-Years
21%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Deferred Income Tax
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Deferred Income Tax
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zymeworks Inc
Glance View

Market Cap
1B USD
Industry
Biotechnology

Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.

ZYME Intrinsic Value
18.33 USD
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Zymeworks Inc's Deferred Income Tax?
Deferred Income Tax
3.5m USD

Based on the financial report for Sep 30, 2024, Zymeworks Inc's Deferred Income Tax amounts to 3.5m USD.

What is Zymeworks Inc's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 3Y
27%

Over the last year, the Deferred Income Tax growth was 73%. The average annual Deferred Income Tax growth rates for Zymeworks Inc have been 27% over the past three years .

Back to Top